Mapping diseases, guiding decisions

With more than 80 product references used routinely in 5 continents for the diagnosis, prognosis and monitoring of thousands of patients with leukemia, including its least common forms, IPSOGEN is currently the world leader in blood cancer molecular diagnostics.

The company is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now.

IPSOGEN relies on its clinical, scientific and technological partnerships, its main investor QIAGEN N.V., and its multidisciplinary team to fulfill its ambition of becoming world leader in the very high-growth market of cancer molecular diagnosis.

This commitment is part of its drive towards personalized medical care, with oncologists already being able to refine their diagnosis and prescribe drugs that are more and more precisely selected, based on tumor genetic profiles.

As a pioneer in personalized medical care, IPSOGEN develops and markets new tools positioned as benchmarks in molecular diagnostics which benefit all stakeholders in healthcare:

• Because the patient’s disease and its state of progression are precisely identified by a standardized diagnostic test, the patient receives personalized more effective, better tolerated treatment and then a better quality of life.
  
  

• The medical practitioner can identify the disease he/she is treating rapidly and precisely and so can provide the patient with a “customized” therapeutic strategy that can be monitored over time and adjusted if necessary in order to achieve optimal effectiveness.
  
  

• Parties involved in heath protection and public health optimize available budget allocation since treatments are prescribed based on biologically rational decisions with improved monitoring of efficacy and safety. Our molecular diagnostic tests also allow early diagnosis and thus help achieve increasingly timely patient care.
  
  

• Pharmaceutical companies can optimize the development process because each new molecule is tested only on patients with a molecular abnormality relevant to the molecule’s  mechanism of action, and who are thus more likely to respond to treatment.

Therefore, by improving patient care and helping to optimize overall healthcare costs, IPSOGEN diagnostic tests provide a perfect way of responding to the new challenges of public health.